The human cytomegalovirus protein pUL13 targets mitochondrial cristae architecture to increase cellular respiration during infection.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
10 08 2021
Historique:
entrez: 4 8 2021
pubmed: 5 8 2021
medline: 18 12 2021
Statut: ppublish

Résumé

Viruses modulate mitochondrial processes during infection to increase biosynthetic precursors and energy output, fueling virus replication. In a surprising fashion, although it triggers mitochondrial fragmentation, the prevalent pathogen human cytomegalovirus (HCMV) increases mitochondrial metabolism through a yet-unknown mechanism. Here, we integrate molecular virology, metabolic assays, quantitative proteomics, and superresolution confocal microscopy to define this mechanism. We establish that the previously uncharacterized viral protein pUL13 is required for productive HCMV replication, targets the mitochondria, and functions to increase oxidative phosphorylation during infection. We demonstrate that pUL13 forms temporally tuned interactions with the mitochondrial contact site and cristae organizing system (MICOS) complex, a critical regulator of cristae architecture and electron transport chain (ETC) function. Stimulated emission depletion superresolution microscopy shows that expression of pUL13 alters cristae architecture. Indeed, using live-cell Seahorse assays, we establish that pUL13 alone is sufficient to increase cellular respiration, not requiring the presence of other viral proteins. Our findings address the outstanding question of how HCMV targets mitochondria to increase bioenergetic output and expands the knowledge of the intricate connection between mitochondrial architecture and ETC function.

Identifiants

pubmed: 34344827
pii: 2101675118
doi: 10.1073/pnas.2101675118
pmc: PMC8364163
pii:
doi:

Substances chimiques

Viral Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : F31 AI154796
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM114141
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007388
Pays : United States

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

J Virol. 2011 Feb;85(4):1573-80
pubmed: 21147915
Curr Top Microbiol Immunol. 2008;325:417-70
pubmed: 18637519
PLoS Pathog. 2006 Dec;2(12):e132
pubmed: 17173481
Nat Methods. 2013 Aug;10(8):730-6
pubmed: 23921808
J Virol. 2010 Feb;84(4):1867-73
pubmed: 19939921
Arch Virol. 2013 Feb;158(2):473-7
pubmed: 23065125
EMBO J. 2020 Jul 15;39(14):e104105
pubmed: 32567732
EMBO J. 2019 Nov 15;38(22):e101056
pubmed: 31609012
Mol Cell Biol. 2002 Apr;22(7):2136-46
pubmed: 11884601
Elife. 2015 May 21;4:
pubmed: 25997101
Nat Commun. 2014;5:3103
pubmed: 24476986
Biochim Biophys Acta. 2015 Feb;1847(2):171-181
pubmed: 25449966
Elife. 2015 Apr 28;4:
pubmed: 25918844
EMBO J. 2011 Oct 18;30(21):4356-70
pubmed: 22009199
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12396-401
pubmed: 14519856
Nat Commun. 2017 May 31;8:15258
pubmed: 28561061
Cell Syst. 2016 Oct 26;3(4):361-373.e6
pubmed: 27641956
Front Microbiol. 2014 May 19;5:218
pubmed: 24904534
J Biol Chem. 1967 Jul 10;242(13):3239-41
pubmed: 6027798
PLoS One. 2016 Aug 01;11(8):e0160258
pubmed: 27479602
J Virol. 2013 Aug;87(15):8481-92
pubmed: 23720730
PLoS One. 2015 Mar 17;10(3):e0120213
pubmed: 25781180
J Biol Chem. 2011 Jan 28;286(4):2918-32
pubmed: 21081504
Nat Biotechnol. 2008 Oct;26(10):1179-86
pubmed: 18820684
Biochem J. 2004 Aug 15;382(Pt 1):331-6
pubmed: 15139850
Mitochondrion. 2011 Nov;11(6):935-45
pubmed: 21907833
Front Cell Infect Microbiol. 2019 Mar 04;9:42
pubmed: 30886834
Sci Rep. 2015 Jan 23;5:7990
pubmed: 25612828
J Virol. 2019 Oct 15;93(21):
pubmed: 31391267
Sci Rep. 2015 Nov 04;5:16064
pubmed: 26530328
Science. 2007 Jun 1;316(5829):1345-8
pubmed: 17540903
Biochim Biophys Acta. 1999 Feb 9;1410(2):103-23
pubmed: 10076021
Expert Rev Anti Infect Ther. 2004 Dec;2(6):881-94
pubmed: 15566332
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
J Virol. 2003 Jan;77(1):631-41
pubmed: 12477866
Biochim Biophys Acta. 2012 Oct;1817(10):1833-8
pubmed: 22409868
Virology. 2015 May;479-480:609-18
pubmed: 25812764
FEBS Lett. 2003 Jul 10;546(2-3):355-8
pubmed: 12832068
Biochim Biophys Acta. 2015 Oct;1853(10 Pt B):2822-33
pubmed: 25595529
Bioinformatics. 2010 Apr 1;26(7):966-8
pubmed: 20147306
Cell Rep. 2018 Nov 13;25(7):1786-1799.e4
pubmed: 30428348
mBio. 2016 Mar 29;7(2):e00029
pubmed: 27025248
J Virol. 2020 Jan 6;94(2):
pubmed: 31694945
Cell Struct Funct. 1998 Apr;23(2):85-93
pubmed: 9669036
Front Pharmacol. 2019 Feb 19;10:98
pubmed: 30837873
Cell Metab. 2008 Nov;8(5):384-98
pubmed: 19046570
Nat Methods. 2011 Jan;8(1):70-3
pubmed: 21131968
Cell Rep. 2020 Jul 28;32(4):107943
pubmed: 32726614
Hepatology. 2009 Aug;50(2):378-86
pubmed: 19591124

Auteurs

Cora N Betsinger (CN)

Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ 08544.

Connor S R Jankowski (CSR)

Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ 08544.

William A Hofstadter (WA)

Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ 08544.

Joel D Federspiel (JD)

Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ 08544.

Clayton J Otter (CJ)

Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ 08544.

Pierre M Jean Beltran (PM)

Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ 08544.

Ileana M Cristea (IM)

Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ 08544 icristea@princeton.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH